CORK, Ireland--(BUSINESS WIRE)--Tibotec Pharmaceuticals, Ltd. announced today that the Committee for Human Medicinal Products (CHMP) in the European Union has granted a positive opinion recommending conditional approval of PREZISTA™ (darunavir, also known by the investigational compound number TMC114), an anti-HIV medication. The CHMP is the committee responsible for the scientific assessment of products seeking one centralised marketing authorisation applicable throughout the European Union. Tibotec anticipates receiving the conditional marketing authorisation from the European Commission by early next year.
